Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
LNCR3
MCID: LNG064
MIFTS: 79

Lung Cancer Susceptibility 3 (LNCR3)

Categories: Cancer diseases, Rare diseases, Respiratory diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Lung Cancer Susceptibility 3

About this section

MalaCards integrated aliases for Lung Cancer Susceptibility 3:

Name: Lung Cancer Susceptibility 3 57 13 72
Lung Adenocarcinoma 12 53 29 6 15 17
Adenocarcinoma of Lung 57 12 75 72
Adenocarcinoma of Lung, Susceptibility to 57
Bronchogenic Lung Adenocarcinoma 12
Non-Small Cell Adenocarcinoma 72
Nonsmall Cell Adenocarcinoma 12
Lung Adenocarcinomas 15
Adenocarcinoma Lung 55
Lncr3 57

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Respiratory diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:3910
OMIM 57 612571
MeSH 44 C538231
NCIt 50 C27745 C3512
UMLS 72 C0152013 C1335060 C2675497
Sources

Summaries for Lung Cancer Susceptibility 3

About this section
NIH Rare Diseases : 53 Lung adenocarcinoma is a cancer that occurs due to abnormal and uncontrolled cell growth in the lungs. It is a subtype of non-small cell lung cancer that is often diagnosed in an outer area of the lung. Early lung cancers may not be associated with any signs and symptoms. As the condition progresses, affected people can experience chest pain, a persistent cough, fatigue, coughing up blood, loss of appetite, unexplained weight loss, shortness of breath, and/or wheezing. The underlying cause of lung adenocarcinoma is generally unknown; however, risk factors for developing a lung cancer include smoking; exposure to secondhand smoke and other toxic chemicals; a family history of lung cancer; previous radiation treatment to the chest or breast; and HIV infection. Treatment varies based on the severity of the condition, the associated signs and symptoms and the affected person's overall health. It may include a combination of surgery, radiation therapy, chemotherapy, targeted therapy, and/or watchful waiting.

MalaCards based summary : Lung Cancer Susceptibility 3, also known as lung adenocarcinoma, is related to mucinous lung adenocarcinoma and lung cancer. An important gene associated with Lung Cancer Susceptibility 3 is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Endostar protein and Endostatins have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and breast, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A lung cancer that derives from epithelial cells of glandular origin.

Wikipedia : 75 Adenocarcinoma of the lung is the most common type of lung cancer, and like other forms of lung cancer,... more...

More information from OMIM: 612571
Sources

Related Diseases for Lung Cancer Susceptibility 3

About this section

Diseases in the Lung Cancer Susceptibility 3 family:

Lung Cancer Susceptibility 1 Lung Cancer Susceptibility 4
Lung Cancer Susceptibility 5

Diseases related to Lung Cancer Susceptibility 3 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 714)
# Related Disease Score Top Affiliating Genes
1 mucinous lung adenocarcinoma 36.2 ROS1 KRAS HRAS ERBB2 EGFR ALK
2 lung cancer 35.8 TP53 STK11 ROS1 RAF1 PRKN PIK3CA
3 lung squamous cell carcinoma 34.9 TP53 ROS1 PIK3CA NFE2L2 KRAS HRAS
4 lung papillary adenocarcinoma 34.6 TP53 NFE2L2 ALK
5 adenocarcinoma 34.0 TP53 STK11 SMAD4 ROS1 RAF1 PIK3CA
6 pancreatic cancer 32.9 TP53 STK11 SMAD4 RAF1 PIK3CA MAP2K1
7 adenoma 32.8 TP53 SMAD4 KRAS CTNNB1 BRAF APC
8 esophageal cancer 32.6 TP53 SMAD4 PIK3CA KRAS HRAS ERBB2
9 colorectal cancer 32.6 TP53 STK11 SMAD4 RAF1 PIK3CA NRAS
10 sarcoma 32.6 TP53 ROS1 RAF1 PIK3CA KRAS HRAS
11 glioblastoma 32.6 TP53 ROS1 PIK3CA NRAS HRAS ERBB2
12 breast cancer 32.5 TP53 STK11 SMAD4 PIK3CA KRAS HRAS
13 hepatocellular carcinoma 32.5 TP53 SMAD4 RAF1 PIK3CA NRAS NFE2L2
14 squamous cell carcinoma 32.5 TP53 STK11 SMAD4 PIK3CA HRAS FGFR3
15 cholangiocarcinoma 32.5 TP53 SMAD4 ROS1 RAF1 PIK3CA KRAS
16 bladder cancer 32.4 TP53 KRAS HRAS FGFR3 ERBB2 EGFR
17 prostate cancer 32.4 TP53 PIK3CA MAP2K1 KRAS HRAS ERBB2
18 gastric adenocarcinoma 32.3 TP53 SMAD4 ROS1 RAF1 PIK3CA NRAS
19 large cell carcinoma 32.3 STK11 ROS1 EGFR
20 colorectal adenocarcinoma 32.3 TP53 KRAS HRAS EGFR CTNNB1 BRAF
21 brain cancer 32.3 TP53 PIK3CA NRAS HRAS EGFR CTNNB1
22 gastric cancer 32.3 TP53 SMAD4 PIK3CA KRAS ERBB2 EGFR
23 cervical cancer 32.3 TP53 STK11 SMAD4 PIK3CA NFE2L2 HRAS
24 melanoma 32.2 TP53 NRAS MAP2K1 CDK4 BRAF
25 bladder urothelial carcinoma 32.2 TP53 PIK3CA NRAS NFE2L2 MAP2K1 KRAS
26 paronychia 32.2 KRAS HRAS EGFR
27 nasopharyngeal carcinoma 32.1 TP53 PIK3CA NRAS HRAS EGFR CDK4
28 glioblastoma multiforme 32.1 TP53 PIK3CA ERBB2 EGFR CDK4
29 noonan syndrome 1 32.1 RAF1 NRAS MAP2K1 KRAS HRAS BRAF
30 differentiated thyroid carcinoma 32.1 TP53 NRAS KRAS HRAS EGFR BRAF
31 peutz-jeghers syndrome 32.1 TP53 STK11 SMAD4 CTNNB1 APC
32 endometrial cancer 32.0 TP53 PIK3CA KRAS HRAS ERBB2 EGFR
33 lynch syndrome 32.0 TP53 KRAS EGFR CTNNB1 BRAF APC
34 adenoid cystic carcinoma 32.0 TP53 PIK3CA KRAS HRAS ERBB2 CTNNB1
35 ovarian cancer 32.0 TP53 PRKN PIK3CA KRAS ERBB2 EGFR
36 glioma 32.0 TP53 PIK3CA ERBB2 EGFR CDK4 BRAF
37 ovary adenocarcinoma 32.0 TP53 PIK3CA KRAS HRAS ERBB2
38 intrahepatic cholangiocarcinoma 32.0 TP53 KRAS EGFR CTNNB1
39 endometrial adenocarcinoma 32.0 TP53 KRAS ERBB2 EGFR CTNNB1
40 renal cell carcinoma, papillary, 1 32.0 TP53 PIK3CA NRAS NFE2L2 HRAS FGFR3
41 familial adenomatous polyposis 31.9 TP53 SMAD4 KRAS CTNNB1 APC
42 in situ carcinoma 31.9 TP53 ERBB2 EGFR
43 estrogen-receptor positive breast cancer 31.9 TP53 PIK3CA ERBB2 EGFR
44 breast adenocarcinoma 31.8 TP53 SMAD4 PIK3CA KRAS ERBB2 EGFR
45 carcinosarcoma 31.8 TP53 PIK3CA KRAS HRAS ERBB2 CTNNB1
46 uterine carcinosarcoma 31.8 TP53 PIK3CA HRAS ERBB2 EGFR CTNNB1
47 ovarian serous cystadenocarcinoma 31.8 TP53 PIK3CA NRAS HRAS ERBB2 BRAF
48 suppression of tumorigenicity 12 31.8 TP53 SMAD4 PIK3CA HRAS CTNNB1 BRAF
49 transitional cell carcinoma 31.8 TP53 HRAS FGFR3 ERBB2 EGFR BRAF
50 lung benign neoplasm 31.8 TP53 RAF1 KRAS HRAS EGFR

Graphical network of the top 20 diseases related to Lung Cancer Susceptibility 3:



Diseases related to Lung Cancer Susceptibility 3
Sources

Symptoms & Phenotypes for Lung Cancer Susceptibility 3

About this section

Clinical features from OMIM:

612571

GenomeRNAi Phenotypes related to Lung Cancer Susceptibility 3 according to GeneCards Suite gene sharing:

26 (show all 27)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 11.2 BRAF EGFR PIK3CA HRAS KRAS
2 Decreased viability GR00106-A-0 11.2 KRAS
3 Decreased viability GR00107-A-1 11.2 MAP2K1
4 Decreased viability GR00221-A-1 11.2 ALK EGFR PIK3CA FGFR3 HRAS NRAS
5 Decreased viability GR00221-A-2 11.2 PIK3CA FGFR3 HRAS KRAS RAF1 ROS1
6 Decreased viability GR00221-A-3 11.2 ERBB2 FGFR3 HRAS MAP2K1 NRAS
7 Decreased viability GR00221-A-4 11.2 ALK BRAF EGFR ERBB2 PIK3CA
8 Decreased viability GR00231-A 11.2 RAF1
9 Decreased viability GR00301-A 11.2 BRAF KRAS RAF1
10 Decreased viability GR00342-S-1 11.2 MAP2K1 ROS1
11 Decreased viability GR00342-S-2 11.2 MAP2K1
12 Decreased viability GR00342-S-3 11.2 MAP2K1
13 Decreased viability GR00381-A-1 11.2 BRAF KRAS
14 Decreased viability GR00402-S-2 11.2 ALK BRAF EGFR ERBB2 PIK3CA FGFR3
15 Decreased substrate adherent cell growth GR00193-A-1 10.33 STK11 RAF1 ROS1
16 Decreased substrate adherent cell growth GR00193-A-2 10.33 CDK4 ALK EGFR RAF1 ROS1
17 Decreased substrate adherent cell growth GR00193-A-3 10.33 BRAF CDK4 FGFR3 STK11
18 Decreased substrate adherent cell growth GR00193-A-4 10.33 BRAF CDK4
19 Decreased cell migration GR00055-A-1 10.15 ALK BRAF CDK4 CTNNB1 EGFR FGFR3
20 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 10.11 APC CDK4 CTNNB1 EGFR ERBB2 FGFR3
21 Decreased viability in esophageal squamous lineage GR00235-A 10.02 APC BRAF CTNNB1 ERBB2 FGFR3 HRAS
22 Decreased cella89culturea89derived Hepatitis C virus (HCVcc; Luca89Jc1) infection GR00234-A-2 9.78 BRAF CDK4 EGFR STK11
23 Decreased Hepatitis C Virus pseudoparticles (HCVpp; H77; genotype 1a) infection GR00234-A-1 9.73 BRAF CDK4 EGFR STK11
24 Increased cell migration GR00055-A-3 9.73 BRAF CTNNB1 EGFR HRAS KRAS PIK3CA
25 Reduced mammosphere formation GR00396-S 9.56 BRAF CDK4 EGFR HRAS KRAS NFE2L2
26 Increased cell viability after pRB stimulation GR00230-A-1 9.46 CDK4 EGFR ERBB2 STK11
27 Upregulation of Wnt/beta-catenin pathway after WNT3A stimulation GR00016-A 9.02 APC BRAF CDK4 ROS1 SMAD4

MGI Mouse Phenotypes related to Lung Cancer Susceptibility 3:

46 (show all 27)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.58 APC BRAF CDK4 CTNNB1 EGFR ERBB2
2 growth/size/body region MP:0005378 10.57 ALK APC BRAF CDK4 CTNNB1 EGFR
3 behavior/neurological MP:0005386 10.56 ALK APC BRAF CDK4 CTNNB1 ERBB2
4 cardiovascular system MP:0005385 10.56 APC BRAF CDK4 CTNNB1 EGFR ERBB2
5 homeostasis/metabolism MP:0005376 10.54 ALK APC BRAF CDK4 CTNNB1 EGFR
6 integument MP:0010771 10.53 ALK APC BRAF CDK4 CTNNB1 EGFR
7 endocrine/exocrine gland MP:0005379 10.5 ALK APC BRAF CDK4 CTNNB1 EGFR
8 craniofacial MP:0005382 10.49 APC BRAF CTNNB1 EGFR ERBB2 FGFR3
9 digestive/alimentary MP:0005381 10.49 APC BRAF CDK4 CTNNB1 EGFR ERBB2
10 mortality/aging MP:0010768 10.49 ALK APC BRAF CDK4 CTNNB1 EGFR
11 embryo MP:0005380 10.48 APC BRAF CDK4 CTNNB1 EGFR ERBB2
12 neoplasm MP:0002006 10.43 ALK APC BRAF CDK4 CTNNB1 EGFR
13 nervous system MP:0003631 10.41 ALK APC BRAF CDK4 CTNNB1 EGFR
14 immune system MP:0005387 10.4 APC BRAF CDK4 CTNNB1 EGFR FGFR3
15 hematopoietic system MP:0005397 10.39 APC BRAF CDK4 CTNNB1 EGFR FGFR3
16 normal MP:0002873 10.33 APC BRAF CDK4 CTNNB1 EGFR ERBB2
17 muscle MP:0005369 10.31 APC BRAF CDK4 CTNNB1 EGFR ERBB2
18 liver/biliary system MP:0005370 10.3 APC BRAF CDK4 CTNNB1 EGFR KRAS
19 hearing/vestibular/ear MP:0005377 10.24 APC BRAF CTNNB1 EGFR FGFR3 KRAS
20 limbs/digits/tail MP:0005371 10.24 APC BRAF CTNNB1 EGFR ERBB2 FGFR3
21 no phenotypic analysis MP:0003012 10.21 CTNNB1 EGFR FGFR3 HRAS KRAS NRAS
22 reproductive system MP:0005389 10.13 ALK APC BRAF CDK4 CTNNB1 EGFR
23 renal/urinary system MP:0005367 10.1 APC BRAF CDK4 CTNNB1 EGFR FGFR3
24 pigmentation MP:0001186 10.02 ALK APC BRAF CDK4 CTNNB1 EGFR
25 respiratory system MP:0005388 9.97 ALK BRAF CTNNB1 EGFR ERBB2 FGFR3
26 skeleton MP:0005390 9.89 ALK APC BRAF CTNNB1 EGFR ERBB2
27 vision/eye MP:0005391 9.47 ALK APC BRAF CDK4 CTNNB1 EGFR
Sources

Drugs & Therapeutics for Lung Cancer Susceptibility 3

About this section

Drugs for Lung Cancer Susceptibility 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 182)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Endostar protein Phase 4
2 Endostatins Phase 4 71581480
3
Gefitinib Approved, Investigational Phase 3 184475-35-2 123631
4
Mesna Approved, Investigational Phase 3 3375-50-6 598
5
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
6
Vinorelbine Approved, Investigational Phase 3 71486-22-1 60780 44424639
7
Ipilimumab Approved Phase 3 477202-00-9
8
Ceritinib Approved Phase 3 1032900-25-6
9
Cetuximab Approved Phase 3 205923-56-4 56842117 2333
10
Meloxicam Approved, Vet_approved Phase 2, Phase 3 71125-38-7 5281106 54677470
11
Pemetrexed Approved, Investigational Phase 3 150399-23-8, 137281-23-3 60843 446556
12
leucovorin Approved Phase 3 58-05-9 143 6006
13
Bevacizumab Approved, Investigational Phase 3 216974-75-3
14
Xylometazoline Approved, Investigational Phase 3 526-36-3 5709
15
Gemcitabine Approved Phase 3 95058-81-4 60750
16
Methylcobalamin Approved, Experimental, Investigational Phase 3 13422-55-4
17
Hydroxocobalamin Approved Phase 3 13422-51-0 11953898 15589840
18
Celecoxib Approved, Investigational Phase 3 169590-42-5 2662
19
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
20
Cyanocobalamin Approved, Nutraceutical Phase 3 68-19-9 44176380
21
Cobalamin Experimental Phase 3 13408-78-1 6857388
22 2,2'-dithiodiethanesulfonic acid Phase 3
23 Shark Cartilage Phase 3
24 Immunoglobulin G Phase 3
25 Endothelial Growth Factors Phase 3
26 Immunologic Factors Phase 2, Phase 3
27 Pharmaceutical Solutions Phase 2, Phase 3
28 Vaccines Phase 2, Phase 3
29 Folic Acid Antagonists Phase 3
30 Nucleic Acid Synthesis Inhibitors Phase 3
31 Vitamin B9 Phase 3
32 Immunosuppressive Agents Phase 3
33 Vitamin B Complex Phase 3
34 Folate Phase 3
35 Antirheumatic Agents Phase 3
36 Angiogenesis Inhibitors Phase 3
37 Angiogenesis Modulating Agents Phase 3
38 Antineoplastic Agents, Immunological Phase 3
39 Anti-Infective Agents Phase 3
40 Antimetabolites Phase 3
41 Antiviral Agents Phase 3
42 Antimetabolites, Antineoplastic Phase 3
43 Analgesics Phase 3
44 Cyclooxygenase Inhibitors Phase 3
45 Analgesics, Non-Narcotic Phase 3
46 Anti-Inflammatory Agents, Non-Steroidal Phase 3
47 Peripheral Nervous System Agents Phase 3
48 Anti-Inflammatory Agents Phase 3
49 Vitamins Phase 3
50 Vitamin B 12 Phase 3

Interventional clinical trials:

(show top 50) (show all 313)
# Name Status NCT ID Phase Drugs
1 Comparative Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma Unknown status NCT02399566 Phase 4 Erlotinib, Pemetrexed
2 Recombinant Human Endostatin Durative Transfusion Combined With Pemetrexed Plus Cisplatin or Carboplatin in the First-line Treatment of Advanced Lung Adenocarcinoma With Wild-type EGFR or ALK-negative Unknown status NCT02804646 Phase 4 recombinant human endostatin;pemetrexed plus cisplatin or carboplatin
3 Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma: a Randomized, Open-label, Multicenter Study Unknown status NCT02103257 Phase 4 Sequential Icotinib Plus Chemotherapy;Icotinib
4 A Randomized ,Opened, Prospective Controlled Trial of Clinical Effectiveness for Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With Epidermal Growth Factor Receptor Gene Mutation Unknown status NCT02283424 Phase 4 Icotinib;chemotherapy (Carboplatin and Docetaxel)
5 Randomized, Open Label, Positive Controlled, Multicenter Trial to Evaluate Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma Unknown status NCT01665417 Phase 4 Experimental;Chemotherapy;Chemotherapy
6 Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Untreated Advanced Non-small-cell Lung Cancer: a Randomized, Open-label Study Unknown status NCT02194556 Phase 4 Sequential and maintenance icotinib;Maintenance icotinib
7 Open Label Study of Erlotinib (Tarceva®) as Single Agent First Line Treatment of Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With Activating Epidermal Growth Factor Receptor (EGFR) Mutations Completed NCT01609543 Phase 4 erlotinib [Tarceva]
8 A Phase III, Multi-center, Randomized Trial of Pemetrexed and Gefitinib in Never-smoker and Adenocarcinoma Patients With Non-small Cell Lung Cancer Previously Treated With Platinum-based Chemotherapy Unknown status NCT01066195 Phase 3 iressa;alimta
9 A Randomized, Phase III Trial of Prophylactic Cranial Irradiation (PCI) in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Are Nonprogressive on Gefitinib or Erlotinib Unknown status NCT00955695 Phase 3 erlotinib hydrochloride;gefitinib
10 Conmana Versus Pemetrexed-based First-line Induction and Maintenance Chemotherapy in Advanced Lung Adenocarcinoma With EGFR-mutation Completed NCT01719536 Phase 3 Icotinib;Chemotherapy
11 A Randomized Phase III Study of Gefitinib (IRESSATM) Versus Standard Chemotherapy (Gemcitabine Plus Cisplatin) as First-line Treatment for in Never Smokers Advance or Metastatic Adenocarcinoma of Lung Completed NCT00455936 Phase 3 Gefitinib
12 A PHASE III STUDY OF ADJUVANT CHEMOTHERAPY AFTER RESECTION FOR PATIENTS WITH T2N0 STAGE I NON-SMALL CELL CARCINOMA OF THE LUNG Completed NCT00002852 Phase 3 paclitaxel;carboplatin
13 A Phase III Prospective Randomized, Double-Blind, Placebo-Controlled Trial of the Epidermal Growth Factor Receptor Antagonist, ZD1839 (IRESSA) in Completely Resected Primary Stage IB, II and IIIA Non-Small Cell Lung Cancer Completed NCT00049543 Phase 3 gefitinib
14 Randomized, Multicenter, Double-blind, Phase 3 Trial of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin Completed NCT00966914 Phase 3 Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel;Placebo in combination with cisplatin and docetaxel or paclitaxel
15 Multicenter, Open-Ended, Double-Blind, Placebo-Controlled, Phase III Study of AE-941 in Addition to Combined Modality Treatment (Chemotherapy/Radiotherapy) for Locally Advanced Unresectable Non-Small Cell Lung Cancer Completed NCT00005838 Phase 3 shark cartilage extract AE-941;cisplatin;vinorelbine tartrate;carboplatin;paclitaxel
16 Phase III Randomized Comparison Study of Vinorelbine, Gemcitabine, and Docetaxel Versus Paclitaxel and Carboplatin in Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00079287 Phase 3 carboplatin;docetaxel;gemcitabine hydrochloride;paclitaxel;vinorelbine tartrate
17 Intercalating and Maintenance Use of Iressa vs. Chemotherapy in Selected Advanced NSCLC: a Randomised Study Completed NCT01404260 Phase 3 Gefitinib;Gemcitabine +Carboplatin
18 Study of Chinese Medicine Plus Targeted Therapy Maintenance Versus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma: A Randomized Double-blind Controlled Clinical Trial Completed NCT02889692 Phase 3 YiQiFang;YangYinFang;YiQiYangYinFang;placebo granules;Erlotinib®;Gefitinib®;Icotinib®
19 Pemetrexed Disodium and Cisplatin Chemotherapy Combined With Synchronous Gefitinib vs Chemotherapy Alone as Adjuvent Therapy in Patient With Stage II-IIIA, Epidermal Growth Factor Receptor Mutant Expressing Lung Adenocarcinoma Recruiting NCT02518802 Phase 3 Gefitinib;Pemetrexed
20 Adjuvant Chemotherapy Versus Observation in Fully Resected Stage I Lung Adenocarcinoma With High Risk of Post-operative Recurrence Recruiting NCT03380468 Phase 2, Phase 3 cisplatin plus pemetrexed
21 A Double-Blind, Randomized, Active-Controlled, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P16 and EU-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer Recruiting NCT03676192 Phase 3 CT-16;Avastin
22 A Multi-center Phase III Randomized Controlled Trial Comparing Between Adjuvant Chemotherapy and Observation in High Risk Patients With Completely Resected Stage Ib Lung Adenocarcinoma Recruiting NCT02281708 Phase 3 vinorelbine plus cisplatin
23 Tyrosine-kinase Inhibitor （TKI） With or Without SBRT in Newly Diagnosed Advanced Staged Lung Adenocarcinoma Recruiting NCT02893332 Phase 3 TKI (Gefitinib or Tarceva )
24 Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) Recruiting NCT02194738 Phase 3 Crizotinib;Erlotinib Hydrochloride
25 Randomized Phase III Trial of Local Consolidation Therapy (LCT) After Nivolumab and Ipilimumab for Immunotherapy-Naive Patients With Metastatic Non-Small Cell Lung Cancer (LONESTAR) -Strategic Alliance: BMS Recruiting NCT03391869 Phase 3
26 Icotinib as an Adjuvant Therapy for Stage II-IIIA Adenocarcinoma With EGFR Mutation: A Placebo-controlled, Randomized, Double-blind, Phase III Study Recruiting NCT02125240 Phase 3 Icotinib;Placebo
27 Phase III Study to Evaluate the Optimal Timing of Postoperative Radiotherapy for High Risk of Locoregional Recurrence Patients With Completely Resected Stage IIIA(N2) Non-Small Cell Lung Cancer Recruiting NCT02974426 Phase 3 Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)
28 Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations Who Did Not Progress After Pemetrexed in Combination With Platinum-based Chemotherapy:a Single-arm, Open, Multicenter Clinical Study. Recruiting NCT03992885 Phase 3 Icotinib
29 A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab With or Without Concurrent Cetuximab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Active, not recruiting NCT00946712 Phase 3 Carboplatin;Paclitaxel
30 A Phase III, Multicenter, Randomized, Open-label Study of Oral LDK378 Versus Standard Chemotherapy in Adult Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer Who Have Been Treated Previously With Chemotherapy (Platinum Doublet) and Crizotinib Active, not recruiting NCT01828112 Phase 3 Ceritinib;pemetrexed;docetaxel
31 A Phase III Multicenter, Randomized Study of Oral LDK378 Versus Standard Chemotherapy in Previously Untreated Adult Patients With ALK Rearranged (ALK-positive), Stage IIIB or IV, Non-squamous Non-small Cell Lung Cancer Active, not recruiting NCT01828099 Phase 3 Ceritinib;Pemetrexed;Cisplatin;Carboplatin
32 Clinical Study of Yiqi-yangyin-jiedu Decoction Combined With Gefitinib in Advanced Pulmonary Adenocarcinoma Patients With Activating EGFR Mutation Enrolling by invitation NCT02929693 Phase 3 gefitinib;Yiqi-yangyin-jiedu decoction;placebo
33 Proteome-based Personalized Immunotherapy of Brain Metastases From Lung Cancer Enrolling by invitation NCT01782287 Phase 2, Phase 3
34 Comparison of Video-assisted Thoracoscopic Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With Microinvasion Not yet recruiting NCT02011997 Phase 3
35 A Randomized, Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced Non-Small-Cell Lung Adenocarcinoma Terminated NCT01798485 Phase 3 Docetaxel;Ganetespib
36 Multicentric, Randomized, Phase III Trial Comparing 2 Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Asymptomatic Brain Metastases Terminated NCT02162537 Phase 3 Cisplatin;Pemetrexed;Bevacizumab
37 Double Blind Randomized Phase III Study of Maintenance Pazopanib Versus Placebo in NSCLC Patients Non Progressive After First Line Chemotherapy. MAPPING, an EORTC Lung Group Study. Terminated NCT01208064 Phase 2, Phase 3 pazopanib hydrochloride
38 A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer Terminated NCT01041781 Phase 3 carboplatin;celecoxib;gemcitabine hydrochloride;pemetrexed disodium
39 Efficacy and Safety of Pemetrexed Plus Cisplatin as Combination Chemotherapy for Post-operative Adenocarcinoma : Multi-center, Single Arm, Open-label, Phase â…¡ Trial Unknown status NCT02498860 Phase 2 Pemebit;Cisplatin
40 The Use of CT Perfusion to Determine the Normalization Window Period in the Treatment of Advanced Primary Lung Adenocarcinoma With Endostar Unknown status NCT01564329 Phase 2 endostar
41 High-dose Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases Unknown status NCT02284490 Phase 2 pemetrexed
42 Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma: A Prospective, Randomised, Open, Multicenter Phase â…¡ Study Unknown status NCT02621333 Phase 2 chemotherapy
43 Crizotinib Combined With Bevacizumab as First-line Therapy in Metastatic Lung Adenocarcinoma Cancer With ALK Translocation or MET Amplification or ROS1 Translocation (CAMAR) Unknown status NCT02946359 Phase 2 Crizotinib, bevacizumab
44 A Randomized Placebo-controlled Phase II Study of Intercalated Administration of Pemetrexed/Cisplatin With Iressa® (Gefitinib) or Placebo as First-line Treatment of Stage IIIB/IV Lung Adenocarcinoma in Never-smokers Unknown status NCT01502202 Phase 2 Gefitinib;Placebo;Pemetrexed plusCIsplatin
45 Survival Analysis of A Chinese Randomized Crossover Study Comparing Erlotinib to Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations Unknown status NCT01131429 Phase 2 Erlotinib;Docetaxel;Cisplatin;Docetaxel;Cisplatin;Erlotinib
46 A Single Armed Phase â…¡Study of Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation Unknown status NCT02737774 Phase 2 Icotinib;Pemetrexed/Carboplatin
47 Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non Small Cell Lung Cancer in Advanced Stage, Which Have Progressed to Chemotherapy. Analysis of Mutations in EGFR and Number of Copies of HER-2 Unknown status NCT01542437 Phase 2 BIBW 2992
48 Pemetrexed and Platinum Use in the Neoadjuvant Setting for Resectable Stage II and IIIA Lung Adenocarcinoma Unknown status NCT02980991 Phase 2 Pemetrexed;Cisplatin
49 A Phase II Study of Erlotinib (OSI-774); Tarceva in Women With Previously Untreated Advance Adenocarcinoma of the Lung Unknown status NCT00137839 Phase 2 Erlotinib
50 A Phase II Study to Assess Efficacy of Combined Treatment With Erlotinib (Tarceva) and Silybin-phytosome (Siliphos) in Patients With EGFR(Epidermal Growth Factor Receptor) Mutant Lung Adenocarcinoma Unknown status NCT02146118 Phase 2 Erlotinib

Search NIH Clinical Center for Lung Cancer Susceptibility 3

Sources

Genetic Tests for Lung Cancer Susceptibility 3

About this section

Genetic tests related to Lung Cancer Susceptibility 3:

# Genetic test Affiliating Genes
1 Lung Adenocarcinoma 29
Sources

Anatomical Context for Lung Cancer Susceptibility 3

About this section

MalaCards organs/tissues related to Lung Cancer Susceptibility 3:

41
Lung, Brain, Breast, Lymph Node, Thyroid, Testes, Endothelial
Sources

Publications for Lung Cancer Susceptibility 3

About this section

Articles related to Lung Cancer Susceptibility 3:

(show top 50) (show all 13083)
# Title Authors PMID Year
1
A genome-wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 22q12.2 in Han Chinese. 8
21725308 2011
2
A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. 8
19836008 2009
3
Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. 8
19151717 2009
4
Lung cancer susceptibility locus at 5p15.33. 8
18978790 2008
5
Common 5p15.33 and 6p21.33 variants influence lung cancer risk. 8
18978787 2008
6
KRAS mutation, KRAS-LCS6 polymorphism, and non-small cell lung cancer. 9 38
19854534 2010
7
HIF-1 alpha signaling is augmented during intermittent hypoxia by induction of the Nrf2 pathway in NOX1-expressing adenocarcinoma A549 cells. 9 38
20347035 2010
8
Comparative proteome analysis of human adenocarcinoma. 9 38
19381893 2010
9
Individuals susceptible to lung adenocarcinoma defined by combined HLA-DQA1 and TERT genotypes. 9 38
20061363 2010
10
Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status. 9 38
19589612 2010
11
Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor status. 9 38
20150826 2010
12
Quantitative analysis of HGF and EGF-dependent phosphotyrosine signaling networks. 9 38
20222723 2010
13
Notch-1 stimulates survival of lung adenocarcinoma cells during hypoxia by activating the IGF-1R pathway. 9 38
20154720 2010
14
Lung adenocarcinoma cells floating in lymphatic vessels resist anoikis by expressing phosphorylated Src. 9 38
20146241 2010
15
Secreted phosphoprotein 1 upstream invasive network construction and analysis of lung adenocarcinoma compared with human normal adjacent tissues by integrative biocomputation. 9 38
19949890 2010
16
Diagnostic value of Her-2/neu, Cyfra 21-1, and carcinoembryonic antigen levels in malignant pleural effusions of lung adenocarcinoma. 9 38
20350214 2010
17
Down-regulation of HSP27 sensitizes TRAIL-resistant tumor cell to TRAIL-induced apoptosis. 9 38
19540014 2010
18
Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. 9 38
20093391 2010
19
Sex differences in estrogen receptor subcellular location and activity in lung adenocarcinoma cells. 9 38
19556604 2010
20
EGFR mutations and the terminal respiratory unit. 9 38
20135199 2010
21
Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma. 9 38
19130320 2010
22
Clinical impact of phosphorylated signal transducer and activator of transcription 3, epidermal growth factor receptor, p53, and vascular endothelial growth factor receptor 1 expression in resected adenocarcinoma of lung by using tissue microarray. 9 38
20052735 2010
23
Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma. 9 38
20007486 2010
24
Usefulness of peptide nucleic acid (PNA)-clamp smart amplification process version 2 (SmartAmp2) for clinical diagnosis of KRAS codon 12 mutations in lung adenocarcinoma: comparison of PNA-clamp SmartAmp2 and PCR-related methods. 9 38
20007840 2010
25
Correlation between epidermal growth factor receptor mutations and expression of female hormone receptors in East-Asian lung adenocarcinomas. 9 38
19875972 2010
26
Naphtho[1,2-b]furan-4,5-dione inactivates EGFR and PI3K/Akt signaling pathways in human lung adenocarcinoma A549 cells. 9 38
20036260 2010
27
Association of p73 G4C14-to-A4T14 polymorphism at exon 2 with the response of human lung adenocarcinoma cell lines to chemotherapy. 9 38
19947923 2010
28
Identification and preliminary characterization of novel small molecules that inhibit growth of human lung adenocarcinoma cells. 9 38
19887599 2009
29
An essential epitope of anti-MUC1 monoclonal antibody KL-6 revealed by focused glycopeptide library. 9 38
19899793 2009
30
ERCC2, ERCC1 polymorphisms and haplotypes, cooking oil fume and lung adenocarcinoma risk in Chinese non-smoking females. 9 38
20003391 2009
31
Association between polymorphisms in DNA repair genes and survival of non-smoking female patients with lung adenocarcinoma. 9 38
20003463 2009
32
A region within the 5'-untranslated region of hypoxia-inducible factor-1alpha mRNA mediates its turnover in lung adenocarcinoma cells. 9 38
19887373 2009
33
COLD-PCR-enhanced high-resolution melting enables rapid and selective identification of low-level unknown mutations. 9 38
19815609 2009
34
Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers. 9 38
19826035 2009
35
Roles of pathologists in molecular targeted cancer therapy. 9 38
19891708 2009
36
Chronic exposure to exogenous matrilysin induces chemoresistance and enhances Bcl-2 expression in A549 lung adenocarcinoma cells. 9 38
19107575 2009
37
Two-round coamplification at lower denaturation temperature-PCR (COLD-PCR)-based sanger sequencing identifies a novel spectrum of low-level mutations in lung adenocarcinoma. 9 38
19760750 2009
38
Laser capture microdissection: a tool for the molecular characterization of histologic subtypes of lung adenocarcinoma. 9 38
19724887 2009
39
Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via VEGF-C. 9 38
19685508 2009
40
Dual role of poly(ADP-ribose) glycohydrolase in the regulation of cell death in oxidatively stressed A549 cells. 9 38
19571039 2009
41
Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: a population-based prospective study. 9 38
19724844 2009
42
Epigenetic silencing of the RASSF1A tumor suppressor gene through HOXB3-mediated induction of DNMT3B expression. 9 38
19854132 2009
43
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. 9 38
19794967 2009
44
Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. 9 38
19826477 2009
45
The cell line secretome, a suitable tool for investigating proteins released in vivo by tumors: application to the study of p53-modulated proteins secreted in lung cancer cells. 9 38
19639960 2009
46
Comparison of FISH, PCR, and immunohistochemistry in assessing EGFR status in lung adenocarcinoma and correlation with clinicopathologic features. 9 38
19704257 2009
47
Cell proliferation and epidermal growth factor signaling in non-small cell lung adenocarcinoma cell lines are dependent on Rin1. 9 38
19570984 2009
48
Restoration of SOCS3 suppresses human lung adenocarcinoma cell growth by downregulating activation of Erk1/2, Akt apart from STAT3. 9 38
19524687 2009
49
Effect of yeast-derived beta-glucan in conjunction with bevacizumab for the treatment of human lung adenocarcinoma in subcutaneous and orthotopic xenograft models. 9 38
19561538 2009
50
Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. 9 38
19706809 2009
Sources

Variations for Lung Cancer Susceptibility 3

About this section

ClinVar genetic disease variations for Lung Cancer Susceptibility 3:

6 (show top 50) (show all 398)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 TP53 NM_000546.5(TP53): c.832C> A (p.Pro278Thr) single nucleotide variant Likely pathogenic,drug response rs17849781 17:7577106-7577106 17:7673788-7673788
2 CDK4 NM_000075.4(CDK4): c.71G> A (p.Arg24His) single nucleotide variant Likely pathogenic,risk factor rs104894340 12:58145430-58145430 12:57751647-57751647
3 FGFR3 NM_000142.4(FGFR3): c.742C> T (p.Arg248Cys) single nucleotide variant Pathogenic rs121913482 4:1803564-1803564 4:1801837-1801837
4 TP53 NM_000546.5(TP53): c.517G> T (p.Val173Leu) single nucleotide variant Pathogenic rs876660754 17:7578413-7578413 17:7675095-7675095
5 TP53 NM_000546.5(TP53): c.818G> T (p.Arg273Leu) single nucleotide variant Pathogenic rs28934576 17:7577120-7577120 17:7673802-7673802
6 SMAD4 NM_005359.5(SMAD4): c.1082G> A (p.Arg361His) single nucleotide variant Pathogenic rs377767347 18:48591919-48591919 18:51065549-51065549
7 PIK3CA NM_006218.4(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic rs121913281 3:178952084-178952084 3:179234296-179234296
8 BRAF NM_004333.6(BRAF): c.1787G> T (p.Gly596Val) single nucleotide variant Pathogenic rs397507483 7:140453148-140453148 7:140753348-140753348
9 BRAF NM_004333.6(BRAF): c.1406G> T (p.Gly469Val) single nucleotide variant Pathogenic rs121913355 7:140481402-140481402 7:140781602-140781602
10 EGFR NM_005228.5(EGFR): c.2156G> C (p.Gly719Ala) single nucleotide variant Pathogenic rs121913428 7:55241708-55241708 7:55174015-55174015
11 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 17:7577539-7577539 17:7674221-7674221
12 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 17:7577548-7577548 17:7674230-7674230
13 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic rs121912655 17:7577556-7577556 17:7674238-7674238
14 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 17:7577547-7577547 17:7674229-7674229
15 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 17:7577548-7577548 17:7674230-7674230
16 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 17:7578190-7578190 17:7674872-7674872
17 HRAS NM_005343.4(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 11:534289-534289 11:534289-534289
18 HRAS NM_005343.4(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 11:534289-534289 11:534289-534289
19 PIK3CA NM_006218.4(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 3:178952085-178952085 3:179234297-179234297
20 PIK3CA NM_006218.4(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 3:178952085-178952085 3:179234297-179234297
21 HRAS NM_005343.4(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 11:534288-534288 11:534288-534288
22 HRAS NM_005343.4(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 11:534286-534286 11:534286-534286
23 PIK3CA NM_006218.4(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 3:178936092-178936092 3:179218304-179218304
24 NRAS NM_002524.5(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs11554290 1:115256529-115256529 1:114713908-114713908
25 RAF1 NM_002880.3(RAF1): c.770C> T (p.Ser257Leu) single nucleotide variant Pathogenic rs80338796 3:12645699-12645699 3:12604200-12604200
26 BRAF NM_004333.6(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 7:140453136-140453136 7:140753336-140753336
27 BRAF NM_004333.6(BRAF): c.1801A> G (p.Lys601Glu) single nucleotide variant Pathogenic rs121913364 7:140453134-140453134 7:140753334-140753334
28 BRAF NM_004333.6(BRAF): c.1405G> C (p.Gly469Arg) single nucleotide variant Pathogenic rs121913357 7:140481403-140481403 7:140781603-140781603
29 BRAF NM_004333.6(BRAF): c.1406G> C (p.Gly469Ala) single nucleotide variant Pathogenic rs121913355 7:140481402-140481402 7:140781602-140781602
30 BRAF NM_004333.6(BRAF): c.1781A> G (p.Asp594Gly) single nucleotide variant Pathogenic rs121913338 7:140453154-140453154 7:140753354-140753354
31 BRAF NM_004333.6(BRAF): c.1406G> A (p.Gly469Glu) single nucleotide variant Pathogenic rs121913355 7:140481402-140481402 7:140781602-140781602
32 ERBB2 NM_004448.3(ERBB2): c.2328_2336dup (p.Val777_Ser779dup) duplication Pathogenic rs587776805 17:37880999-37881007 17:39724746-39724754
33 ERBB2 NM_004448.3(ERBB2): c.2606T> G (p.Leu869Arg) single nucleotide variant Pathogenic rs1131692237 17:37881414-37881414 17:39725161-39725161
34 EGFR NM_005228.5(EGFR): c.2492G> A (p.Arg831His) single nucleotide variant Pathogenic rs150036236 7:55259434-55259434 7:55191741-55191741
35 EGFR NM_005228.5(EGFR): c.988G> A (p.Glu330Lys) single nucleotide variant Pathogenic rs139429793 7:55223621-55223621 7:55155928-55155928
36 PRKN NM_013988.2(PARK2): c.(8_8)_(171_171)+180544del deletion Pathogenic
37 SMAD4 NM_005359.5(SMAD4): c.1081C> T (p.Arg361Cys) single nucleotide variant Pathogenic rs80338963 18:48591918-48591918 18:51065548-51065548
38 NRAS NM_002524.5(NRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic rs121913255 1:115256528-115256528 1:114713907-114713907
39 PIK3CA NM_006218.4(PIK3CA): c.2176G> A (p.Glu726Lys) single nucleotide variant Pathogenic rs867262025 3:178938934-178938934 3:179221146-179221146
40 TP53 NM_000546.5(TP53): c.713G> T (p.Cys238Phe) single nucleotide variant Pathogenic rs730882005 17:7577568-7577568 17:7674250-7674250
41 TP53 NM_000546.5(TP53): c.712T> C (p.Cys238Arg) single nucleotide variant Pathogenic rs1057519981 17:7577569-7577569 17:7674251-7674251
42 TP53 NM_000546.5(TP53): c.841G> T (p.Asp281Tyr) single nucleotide variant Pathogenic rs764146326 17:7577097-7577097 17:7673779-7673779
43 TP53 NM_000546.5(TP53): c.841G> A (p.Asp281Asn) single nucleotide variant Pathogenic rs764146326 17:7577097-7577097 17:7673779-7673779
44 TP53 NM_000546.5(TP53): c.537T> G (p.His179Gln) single nucleotide variant Pathogenic rs876660821 17:7578393-7578393 17:7675075-7675075
45 TP53 NM_000546.5(TP53): c.659A> G (p.Tyr220Cys) single nucleotide variant Pathogenic rs121912666 17:7578190-7578190 17:7674872-7674872
46 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic rs587778720 17:7578211-7578211 17:7674893-7674893
47 TP53 NM_000546.5(TP53): c.422G> A (p.Cys141Tyr) single nucleotide variant Pathogenic rs587781288 17:7578508-7578508 17:7675190-7675190
48 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic rs28934574 17:7577094-7577094 17:7673776-7673776
49 TP53 NM_000546.5(TP53): c.842A> G (p.Asp281Gly) single nucleotide variant Pathogenic rs587781525 17:7577096-7577096 17:7673778-7673778
50 TP53 NM_000546.5(TP53): c.488A> G (p.Tyr163Cys) single nucleotide variant Pathogenic rs148924904 17:7578442-7578442 17:7675124-7675124

Copy number variations for Lung Cancer Susceptibility 3 from CNVD:

7 (show top 50) (show all 580)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13394 1 1 2300000 Gain Lung adenocarcinoma
2 13409 1 1 2300000 Gain Lung adenocarcinoma
3 13970 1 102000000 107000000 Loss Lung adenocarcinoma
4 13986 1 102200000 107200000 Loss Lung adenocarcinoma
5 14528 1 109314358 109386258 Deletion WDR47 Lung adenocarcinoma
6 15384 1 115048600 115061038 Copy number NRAS Lung adenocarcinoma
7 17560 1 143480000 149410000 Amplification ARNT Lung adenocarcinoma
8 18143 1 144218994 144222801 Amplification RBM8A Lung adenocarcinoma
9 18161 1 144227739 144235088 Amplification PEX11B Lung adenocarcinoma
10 18176 1 144287344 144297903 Amplification PIAS3 Lung adenocarcinoma
11 18223 1 144475951 145932379 Amplification GPR89A Lung adenocarcinoma
12 18385 1 145180914 145234067 Amplification CHD1L Lung adenocarcinoma
13 18405 1 145479805 145564639 Amplification BCL9 Lung adenocarcinoma
14 18433 1 145585791 145609258 Amplification ACP6 Lung adenocarcinoma
15 19003 1 148137824 148138969 Amplification BOLA1 Lung adenocarcinoma
16 19039 1 148305965 148384129 Amplification VPS45 Lung adenocarcinoma
17 19152 1 148885329 148936257 Amplification GOLPH3L Lung adenocarcinoma
18 19199 1 149165511 149203837 Amplification SETDB1 Lung adenocarcinoma
19 19207 1 149221122 149234738 Amplification ANXA9 Lung adenocarcinoma
20 19214 1 149247596 149274813 Amplification PRUNE Lung adenocarcinoma
21 19280 1 149399337 149404960 Amplification LYSMD1 Lung adenocarcinoma
22 19287 1 149415557 149429264 Amplification VPS72 Lung adenocarcinoma
23 19299 1 149493820 149506578 Amplification PSMD4 Lung adenocarcinoma
24 19341 1 149638664 149641036 Amplification PSMB4 Lung adenocarcinoma
25 19375 1 149998746 150002664 Amplification MRPL9 Lung adenocarcinoma
26 19378 1 150009206 150029634 Amplification TDRKH Lung adenocarcinoma
27 19432 1 150271605 150276135 Amplification S100A11 Lung adenocarcinoma
28 20047 1 152787674 152797744 Amplification UBE2Q1 Lung adenocarcinoma
29 20052 1 152821157 152867061 Amplification ADAR Lung adenocarcinoma
30 20569 1 153196125 153200882 Amplification PYGO2 Lung adenocarcinoma
31 20571 1 153201397 153213464 Amplification SHC1 Lung adenocarcinoma
32 20591 1 153213790 153218346 Amplification CKS1B Lung adenocarcinoma
33 20592 1 153222440 153232211 Amplification FLAD1 Lung adenocarcinoma
34 20617 1 153302836 153308653 Amplification EFNA4 Lung adenocarcinoma
35 20622 1 153317971 153326638 Amplification EFNA3 Lung adenocarcinoma
36 20838 1 154761820 154809020 Amplification IQGAP3 Lung adenocarcinoma
37 20853 1 154828181 154830715 Amplification APOA1BP Lung adenocarcinoma
38 20863 1 154936029 154941999 Amplification CRABP2 Lung adenocarcinoma
39 20868 1 154959036 154964835 Amplification ISG20L2 Lung adenocarcinoma
40 20872 1 154973717 154977547 Amplification MRPL24 Lung adenocarcinoma
41 20875 1 154978522 155003341 Amplification HDGF Lung adenocarcinoma
42 20983 1 155749790 155788934 Amplification FCRL5 Lung adenocarcinoma
43 21047 1 156490550 156494682 Amplification CD1A Lung adenocarcinoma
44 21335 1 158163454 158182010 Amplification IGSF9 Lung adenocarcinoma
45 21364 1 158264085 158268407 Amplification PIGM Lung adenocarcinoma
46 21422 1 158525000 158579978 Amplification COPA Lung adenocarcinoma
47 21516 1 159308119 159325966 Amplification PVRL4 Lung adenocarcinoma
48 21522 1 159336969 159354490 Amplification PFDN2 Lung adenocarcinoma
49 21527 1 159354514 159361857 Amplification NIT1 Lung adenocarcinoma
50 21533 1 159390157 159395270 Amplification UFC1 Lung adenocarcinoma
Sources

Expression for Lung Cancer Susceptibility 3

About this section
LifeMap Discovery
Genes differentially expressed in tissues of Lung Cancer Susceptibility 3 patients vs. healthy controls: 35 (show all 45)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 TNNC1 troponin C type 1 (slow) Lung - 5.28 0.000
2 COL11A1 collagen, type XI, alpha 1 Lung + 5.07 0.000
3 MMP1 matrix metallopeptidase 1 Lung + 4.75 0.000
4 AGER advanced glycosylation end product-specific receptor Lung - 4.69 0.000
5 WIF1 WNT inhibitory factor 1 Lung - 4.60 0.000
6 SOSTDC1 sclerostin domain containing 1 Lung - 4.47 0.000
7 FABP4 fatty acid binding protein 4, adipocyte Lung - 4.32 0.000
8 CDH3 cadherin 3, type 1, P-cadherin (placental) Lung + 4.31 0.000
9 FOSB FBJ murine osteosarcoma viral oncogene homolog B Lung - 4.24 0.000
10 TMEM100 transmembrane protein 100 Lung - 4.20 0.000
11 CLEC3B C-type lectin domain family 3, member B Lung - 4.18 0.000
12 FCN3 ficolin (collagen/fibrinogen domain containing) 3 Lung - 4.17 0.000
13 MT1M metallothionein 1M Lung - 4.07 0.000
14 SPP1 secreted phosphoprotein 1 Lung + 4.04 0.000
15 SPINK1 serine peptidase inhibitor, Kazal type 1 Lung + 3.96 0.000
16 COL10A1 collagen, type X, alpha 1 Lung + 3.79 0.000
17 CLIC5 chloride intracellular channel 5 Lung - 3.65 0.000
18 ADIRF adipogenesis regulatory factor Lung - 3.65 0.000
19 RAMP2 receptor (G protein-coupled) activity modifying protein 2 Lung - 3.62 0.000
20 HIGD1B HIG1 hypoxia inducible domain family, member 1B Lung - 3.60 0.000
21 STXBP6 syntaxin binding protein 6 (amisyn) Lung - 3.59 0.000
22 TMPRSS4 transmembrane protease, serine 4 Lung + 3.53 0.000
23 EFCC1 EF-hand and coiled-coil domain containing 1 Lung - 3.47 0.000
24 MFAP4 microfibrillar-associated protein 4 Lung - 3.47 0.000
25 ABCC3 ATP-binding cassette, sub-family C (CFTR/MRP), member 3 Lung + 3.47 0.000
26 TOP2A topoisomerase (DNA) II alpha Lung + 3.41 0.000
27 TCF21 transcription factor 21 Lung - 3.38 0.000
28 CA4 carbonic anhydrase IV Lung - 3.38 0.000
29 CYP4B1 cytochrome P450, family 4, subfamily B, polypeptide 1 Lung - 3.33 0.000
30 GPM6A glycoprotein M6A Lung - 3.30 0.000
31 GINS2 GINS complex subunit 2 (Psf2 homolog) Lung + 3.29 0.000
32 NEK2 NIMA-related kinase 2 Lung + 3.27 0.000
33 TOX3 TOX high mobility group box family member 3 Lung + 3.24 0.000
34 IL1RL1 interleukin 1 receptor-like 1 Lung - 3.21 0.000
35 PKNOX2 PBX/knotted 1 homeobox 2 Lung - 3.21 0.000
36 ABCA8 ATP-binding cassette, sub-family A (ABC1), member 8 Lung - 3.17 0.000
37 SCGB1A1 secretoglobin, family 1A, member 1 (uteroglobin) Lung - 3.17 0.000
38 FIGF c-fos induced growth factor (vascular endothelial growth factor D) Lung - 3.14 0.000
39 CRABP2 cellular retinoic acid binding protein 2 Lung + 3.11 0.000
40 SGCG sarcoglycan, gamma (35kDa dystrophin-associated glycoprotein) Lung - 3.10 0.000
41 ADAMTS8 ADAM metallopeptidase with thrombospondin type 1 motif, 8 Lung - 3.08 0.000
42 SFTPD surfactant protein D Lung - 3.07 0.000
43 MARCO macrophage receptor with collagenous structure Lung - 3.07 0.000
44 COL1A1 collagen, type I, alpha 1 Lung + 3.05 0.000
45 NMU neuromedin U Lung + 3.05 0.000
Search GEO for disease gene expression data for Lung Cancer Susceptibility 3.
Sources

Pathways for Lung Cancer Susceptibility 3

About this section

Pathways related to Lung Cancer Susceptibility 3 according to GeneCards Suite gene sharing:

(show top 50) (show all 211)
# Super pathways Score Top Affiliating Genes
1
Signaling by GPCR 66
Show member pathways
 14.39 TP53 STK11 SMAD4 RAF1 PIK3CA NRAS
2
Innate Immune System 66
Show member pathways
 14.22 TP53 RAF1 PRKN PIK3CA NRAS MAP2K1
3
ERK Signaling 64
Show member pathways
 14.03 TP53 STK11 SMAD4 ROS1 RAF1 NRAS
4
Apoptotic Pathways in Synovial Fibroblasts 64
Show member pathways
 14.02 TP53 RAF1 NRAS MAP2K1 KRAS HRAS
5
HIV Life Cycle 66
Show member pathways
 13.95 SMAD4 RAF1 PIK3CA NRAS MAP2K1 KRAS
6
GPCR Pathway 64
Show member pathways
 13.95 TP53 SMAD4 ROS1 RAF1 NRAS MAP2K1
7
PEDF Induced Signaling 64
Show member pathways
 13.91 TP53 SMAD4 ROS1 RAF1 NRAS MAP2K1
8
Activation of cAMP-Dependent PKA 64
Show member pathways
 13.79 SMAD4 ROS1 RAF1 NRAS MAP2K1 KRAS
9
TGF-Beta Pathway 64
Show member pathways
 13.76 TP53 SMAD4 ROS1 RAF1 PIK3CA NRAS
10
Developmental Biology 66
Show member pathways
 13.74 SMAD4 RAF1 PIK3CA NRAS MAP2K1 KRAS
11
Class I MHC mediated antigen processing and presentation 66
Show member pathways
 13.68 TP53 RAF1 PRKN PIK3CA NRAS KRAS
12
Akt Signaling 64
Show member pathways
 13.65 TP53 ROS1 RAF1 NRAS KRAS HRAS
13
Integrin Pathway 64
Show member pathways
 13.61 RAF1 PIK3CA NRAS MAP2K1 KRAS HRAS
14
Cytokine Signaling in Immune system 66
Show member pathways
 13.6 TP53 RAF1 PIK3CA NRAS MAP2K1 KRAS
15
CREB Pathway 64
Show member pathways
 13.57 ROS1 RAF1 NRAS MAP2K1 KRAS HRAS
16
Nanog in Mammalian ESC Pluripotency 64
Show member pathways
 13.5 ROS1 RAF1 NRAS MAP2K1 KRAS HRAS
17
PAK Pathway 64
Show member pathways
 13.49 SMAD4 NRAS KRAS HRAS FGFR3 ERBB2
18
IL-2 Pathway 64
Show member pathways
 13.45 TP53 RAF1 NRAS MAP2K1 KRAS HRAS
19
Phospholipase-C Pathway 64
Show member pathways
 13.33 TP53 RAF1 NRAS MAP2K1 KRAS HRAS
20
p70S6K Signaling 64
Show member pathways
 13.31 STK11 RAF1 NRAS MAP2K1 KRAS HRAS
21
G-Beta Gamma Signaling 64
Show member pathways
 13.27 RAF1 NRAS MAP2K1 KRAS HRAS EGFR
22
fMLP Pathway 64
Show member pathways
 13.26 TP53 RAF1 NRAS MAP2K1 KRAS HRAS
23
Circadian entrainment 37
Show member pathways
 13.24 RAF1 PIK3CA NRAS MAP2K1 KRAS HRAS
24
TNFR1 Pathway 64
Show member pathways
 13.22 TP53 RAF1 PIK3CA NRAS MAP2K1 KRAS
25
Human cytomegalovirus infection 37
Show member pathways
 13.22 TP53 SMAD4 RAF1 PIK3CA NRAS MAP2K1
26
Actin Nucleation by ARP-WASP Complex 64
Show member pathways
 13.2 ROS1 RAF1 HRAS FGFR3 ERBB2 EGFR
27
Development Angiotensin activation of ERK 22
Show member pathways
 13.19 TP53 RAF1 PIK3CA NRAS MAP2K1 KRAS
28
Sertoli-Sertoli Cell Junction Dynamics 64
Show member pathways
 13.18 RAF1 NRAS MAP2K1 KRAS HRAS CTNNB1
29
Regulation of lipid metabolism Insulin signaling-generic cascades 22
Show member pathways
 13.17 RAF1 PIK3CA NRAS MAP2K1 KRAS HRAS
30
Focal Adhesion 37 1
Show member pathways
 13.17 RAF1 PIK3CA NRAS MAP2K1 KRAS HRAS
31
NFAT and Cardiac Hypertrophy 64
Show member pathways
 13.13 RAF1 PIK3CA NRAS MAP2K1 KRAS HRAS
32
CCR5 Pathway in Macrophages 64
Show member pathways
 13.11 RAF1 PIK3CA NRAS MAP2K1 KRAS HRAS
33
TCR Signaling (Qiagen) 64
Show member pathways
 13.09 TP53 RAF1 NRAS MAP2K1 KRAS HRAS
34
MAPK-Erk Pathway 67
Show member pathways
 13.08 STK11 RAF1 PIK3CA NRAS MAP2K1 KRAS
35
Apoptosis Modulation and Signaling 1
Show member pathways
 13.05 TP53 RAF1 PIK3CA NRAS MAP2K1 KRAS
36
Beta-Adrenergic Signaling 64
Show member pathways
 13.05 RAF1 NRAS MAP2K1 KRAS HRAS CTNNB1
37
MAPK signaling pathway 37 1
13.04 TP53 RAF1 NRAS MAP2K1 KRAS HRAS
38
Ras signaling pathway 37
Show member pathways
 13.01 RAF1 PIK3CA NRAS MAP2K1 KRAS HRAS
39
Downstream signaling events of B Cell Receptor (BCR) 66
Show member pathways
 13 TP53 PIK3CA NRAS KRAS HRAS FGFR3
40
PI3K-Akt signaling pathway 37
Show member pathways
 13 TP53 STK11 RAF1 PIK3CA NRAS MAP2K1
41
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 65
Show member pathways
 12.98 RAF1 PIK3CA MAP2K1 KRAS HRAS BRAF
42
Development HGF signaling pathway 22
Show member pathways
 12.98 TP53 RAF1 PIK3CA NRAS MAP2K1 KRAS
43
4-1BB Pathway 64
Show member pathways
 12.96 TP53 RAF1 NRAS MAP2K1 KRAS HRAS
44
Development Endothelin-1/EDNRA signaling 22
Show member pathways
 12.94 RAF1 PIK3CA NRAS MAP2K1 KRAS HRAS
45
G-AlphaQ Signaling 64
Show member pathways
 12.93 RAF1 NRAS MAP2K1 KRAS HRAS EGFR
46
Regulation of actin cytoskeleton 37 1
12.89 RAF1 PIK3CA NRAS MAP2K1 KRAS HRAS
47
Immune response IL-23 signaling pathway 22
Show member pathways
 12.87 TP53 PIK3CA NRAS KRAS HRAS ERBB2
48
ErbB signaling pathway 37 1
Show member pathways
 12.87 TP53 RAF1 PIK3CA NRAS MAP2K1 KRAS
49
T cell receptor signaling pathway 37
Show member pathways
 12.84 RAF1 PIK3CA NRAS MAP2K1 KRAS HRAS
50
Immune response Fc epsilon RI pathway 22
Show member pathways
 12.82 RAF1 PIK3CA NRAS MAP2K1 KRAS HRAS
Sources

GO Terms for Lung Cancer Susceptibility 3

About this section

Cellular components related to Lung Cancer Susceptibility 3 according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 protein-containing complex GO:0032991 9.93 TP53 PRKN EGFR CTNNB1 CDK4 ALK
2 focal adhesion GO:0005925 9.88 MAP2K1 KRAS FGFR3 EGFR CTNNB1
3 receptor complex GO:0043235 9.72 ROS1 FGFR3 ERBB2 EGFR ALK
4 perinuclear region of cytoplasm GO:0048471 9.56 ROS1 PRKN HRAS ERBB2 EGFR CTNNB1
5 cytoplasm GO:0005737 9.55 TP53 STK11 SMAD4 RAF1 PRKN PIK3CA
6 Wnt signalosome GO:1990909 9.49 CTNNB1 APC
7 nucleus GO:0005634 10.31 TP53 STK11 SMAD4 RAF1 PRKN NFE2L2
8 membrane GO:0016020 10.3 TP53 STK11 ROS1 RAF1 PIK3CA NRAS
9 cytosol GO:0005829 10.1 TP53 STK11 SMAD4 RAF1 PRKN PIK3CA
10 plasma membrane GO:0005886 10.03 ROS1 RAF1 PIK3CA NRAS NFE2L2 MAP2K1
11 Golgi apparatus GO:0005794 10.01 RAF1 PRKN NRAS NFE2L2 MAP2K1 HRAS

Biological processes related to Lung Cancer Susceptibility 3 according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of protein kinase B signaling GO:0051897 9.99 PIK3CA FGFR3 ERBB2 EGFR
2 regulation of cell proliferation GO:0042127 9.99 SMAD4 EGFR CTNNB1 CDK4 BRAF ALK
3 protein autophosphorylation GO:0046777 9.98 STK11 FGFR3 ERBB2 EGFR ALK
4 T cell receptor signaling pathway GO:0050852 9.97 STK11 PIK3CA HRAS BRAF
5 negative regulation of neuron apoptotic process GO:0043524 9.97 PRKN PIK3CA KRAS HRAS BRAF
6 cell cycle arrest GO:0007050 9.96 TP53 STK11 MAP2K1 HRAS APC
7 peptidyl-tyrosine phosphorylation GO:0018108 9.95 ROS1 MAP2K1 FGFR3 ERBB2 EGFR BRAF
8 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.93 ROS1 ERBB2 EGFR ALK
9 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.92 RAF1 PIK3CA EGFR BRAF
10 Ras protein signal transduction GO:0007265 9.91 TP53 NRAS KRAS HRAS
11 cellular response to drug GO:0035690 9.9 TP53 NFE2L2 EGFR BRAF
12 phosphorylation GO:0016310 9.9 STK11 ROS1 RAF1 PIK3CA MAP2K1 FGFR3
13 liver development GO:0001889 9.89 PIK3CA KRAS EGFR
14 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.89 RAF1 NRAS KRAS HRAS
15 negative regulation of cell death GO:0060548 9.88 SMAD4 PRKN NFE2L2
16 positive regulation of epithelial cell proliferation GO:0050679 9.88 HRAS ERBB2 EGFR
17 positive regulation of MAP kinase activity GO:0043406 9.88 KRAS HRAS ERBB2 EGFR
18 cellular response to growth factor stimulus GO:0071363 9.87 ERBB2 EGFR CTNNB1
19 somatic stem cell population maintenance GO:0035019 9.86 SMAD4 RAF1 BRAF
20 activation of MAPKK activity GO:0000186 9.86 RAF1 EGFR BRAF
21 regulation of cell differentiation GO:0045595 9.85 RAF1 CTNNB1 APC
22 positive regulation of axonogenesis GO:0050772 9.85 STK11 MAP2K1 BRAF
23 positive regulation of MAPK cascade GO:0043410 9.85 HRAS FGFR3 ERBB2 CTNNB1
24 negative regulation of apoptotic process GO:0043066 9.85 TP53 RAF1 EGFR CTNNB1 BRAF
25 regulation of cell motility GO:2000145 9.84 RAF1 ERBB2 EGFR
26 ERBB2 signaling pathway GO:0038128 9.83 PIK3CA ERBB2 EGFR
27 regulation of ERK1 and ERK2 cascade GO:0070372 9.83 ROS1 ERBB2 EGFR
28 thymus development GO:0048538 9.83 RAF1 MAP2K1 CTNNB1 BRAF
29 positive regulation of protein phosphorylation GO:0001934 9.83 RAF1 KRAS HRAS ERBB2 EGFR
30 vasculature development GO:0001944 9.82 STK11 PIK3CA CTNNB1
31 thyroid gland development GO:0030878 9.8 RAF1 MAP2K1 BRAF
32 face development GO:0060324 9.79 RAF1 MAP2K1 BRAF
33 cell proliferation GO:0008283 9.73 TP53 SMAD4 ROS1 EGFR CTNNB1 ALK
34 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.72 MAP2K1 HRAS FGFR3 EGFR BRAF
35 regulation of microtubule-based process GO:0032886 9.71 ERBB2 APC
36 anoikis GO:0043276 9.71 STK11 PIK3CA
37 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.71 TP53 MAP2K1 EGFR
38 response to isolation stress GO:0035900 9.7 KRAS HRAS
39 regulation of axon regeneration GO:0048679 9.7 MAP2K1 BRAF
40 protein phosphorylation GO:0006468 9.7 STK11 ROS1 RAF1 PIK3CA MAP2K1 FGFR3
41 trachea formation GO:0060440 9.69 MAP2K1 CTNNB1
42 negative regulation of ERBB signaling pathway GO:1901185 9.69 ERBB2 EGFR
43 phosphatidylinositol phosphorylation GO:0046854 9.35 PIK3CA
44 MAPK cascade GO:0000165 9.28 RAF1 NRAS MAP2K1 KRAS HRAS FGFR3
45 signal transduction GO:0007165 10.31 RAF1 NRAS MAP2K1 KRAS HRAS ERBB2
46 positive regulation of transcription by RNA polymerase II GO:0045944 10.24 TP53 SMAD4 RAF1 PRKN NFE2L2 HRAS
47 positive regulation of transcription, DNA-templated GO:0045893 10.16 TP53 SMAD4 NFE2L2 MAP2K1 EGFR CTNNB1
48 positive regulation of cell proliferation GO:0008284 10.15 KRAS HRAS FGFR3 EGFR CTNNB1 CDK4
49 negative regulation of cell proliferation GO:0008285 10.1 TP53 STK11 SMAD4 RAF1 MAP2K1 HRAS
50 negative regulation of gene expression GO:0010629 10.04 ROS1 PRKN MAP2K1 HRAS CTNNB1

Molecular functions related to Lung Cancer Susceptibility 3 according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.99 TP53 PRKN EGFR CTNNB1 APC
2 enzyme binding GO:0019899 9.96 TP53 RAF1 PRKN EGFR CTNNB1
3 protein C-terminus binding GO:0008022 9.88 MAP2K1 HRAS ERBB2 CTNNB1
4 protein phosphatase binding GO:0019903 9.88 TP53 ROS1 ERBB2 EGFR CTNNB1
5 protein kinase activity GO:0004672 9.85 STK11 ROS1 RAF1 MAP2K1 FGFR3 ERBB2
6 protein tyrosine kinase activity GO:0004713 9.8 ROS1 MAP2K1 FGFR3 ERBB2 EGFR BRAF
7 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.77 ROS1 FGFR3 ERBB2 EGFR ALK
8 RNA polymerase II transcription factor binding GO:0001085 9.74 TP53 SMAD4 CTNNB1
9 MAP kinase kinase kinase activity GO:0004709 9.72 RAF1 EGFR BRAF
10 kinase activity GO:0016301 9.7 STK11 ROS1 RAF1 PIK3CA MAP2K1 FGFR3
11 I-SMAD binding GO:0070411 9.6 SMAD4 CTNNB1
12 LRR domain binding GO:0030275 9.58 STK11 KRAS
13 transmembrane signaling receptor activity GO:0004888 9.54 ERBB2 EGFR
14 nucleotide binding GO:0000166 9.32 RAF1 NRAS MAP2K1 KRAS HRAS FGFR3
15 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.21 PIK3CA
16 protein binding GO:0005515 10.46 TP53 STK11 SMAD4 ROS1 RAF1 PRKN
17 transferase activity GO:0016740 10.18 STK11 ROS1 RAF1 PRKN PIK3CA MAP2K1
18 identical protein binding GO:0042802 10.13 TP53 SMAD4 RAF1 PRKN FGFR3 ERBB2
19 ATP binding GO:0005524 10.1 TP53 STK11 ROS1 RAF1 PIK3CA MAP2K1
20 protein heterodimerization activity GO:0046982 10.04 TP53 SMAD4 RAF1 ERBB2 EGFR CTNNB1
21 protein serine/threonine kinase activity GO:0004674 10 STK11 RAF1 PIK3CA MAP2K1 CDK4 BRAF
Sources

Sources for Lung Cancer Susceptibility 3

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....